Nasdaq · CIK 0001868279
AVBP ArriVent BioPharma, Inc.
Insider trading from SEC Form 4. Last filing Jun 22, 2026. Close $16.73 on Oct 9, 2026, +11% from the 52-week low and -52% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
AVBPOct 9, 2026 · close 16.73
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ArriVent BioPharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Hillhouse Investment Management, Ltd. owner sell | $13M 555,555 shares | -12% | - |
Transactions
The last 26 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | John Hohneker director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,562 | $0.00 | $0 | 13,562 | Jun 22, 2026 |
| Jun 18, 2026 | Kristine Peterson director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,562 | $0.00 | $0 | 13,562 | Jun 22, 2026 |
| Jun 18, 2026 | Merdad Parsey director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,562 | $0.00 | $0 | 13,562 | Jun 22, 2026 |
| Jun 18, 2026 | Chris Nolet director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,562 | $0.00 | $0 | 13,562 | Jun 22, 2026 |
| Feb 2, 2026 | James Paul Kastenmayer General Counsel | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 4, 2026 |
| Feb 2, 2026 | Zhengbin Yao President and CEO | AGrant or award Stock Option (right to buy)derivative | +550,000 | $0.00 | $0 | 550,000 | Feb 4, 2026 |
| Feb 2, 2026 | Winston Kung Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 4, 2026 |
| Feb 2, 2026 | Stuart Lutzker President of R&D | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 4, 2026 |
| Feb 2, 2026 | Robin LaChapelle Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 4, 2026 |
| Dec 10, 2025 | Hillhouse Investment Management, Ltd. owner | SOpen-market sale Common Stockindirect: See footnotes | -555,555 | $23.37 | $13M | 3,929,117 | Feb 3, 2026 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Common Stock | +2,050 | $2.28 | $4,674 | 126,633 | Jul 15, 2025 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Common Stock | +2,600 | $2.28 | $5,928 | 129,233 | Jul 15, 2025 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Common Stock | +6,503 | $2.28 | $15k | 135,736 | Jul 15, 2025 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Stock Option (right to buy)derivative | -2,050 | $0.00 | $0 | 410 | Jul 15, 2025 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Stock Option (right to buy)derivative | -2,600 | $0.00 | $0 | 12,873 | Jul 15, 2025 |
| Jul 11, 2025 | Robin LaChapelle Chief Operating Officer | MOption exercise Stock Option (right to buy)derivative | -6,503 | $0.00 | $0 | 6,370 | Jul 15, 2025 |
| Jun 18, 2025 | Chris Nolet director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
| Jun 18, 2025 | John Hohneker director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
| Jun 18, 2025 | Kristine Peterson director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
| Jun 18, 2025 | Merdad Parsey director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
| Apr 28, 2025 | Merdad Parsey director | AGrant or award Stock Option (right to buy)derivative | +28,346 | $0.00 | $0 | 28,346 | Apr 29, 2025 |
| Feb 3, 2025 | James Paul Kastenmayer General Counsel | AGrant or award Stock Option (right to buy)derivative | +102,000 | $0.00 | $0 | 102,000 | Feb 14, 2025 |
| Feb 3, 2025 | Winston Kung Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 14, 2025 |
| Feb 3, 2025 | Robin LaChapelle Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 14, 2025 |
| Feb 3, 2025 | Stuart Lutzker President of R&D | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 14, 2025 |
| Feb 3, 2025 | Zhengbin Yao President and CEO | AGrant or award Stock Option (right to buy)derivative | +380,000 | $0.00 | $0 | 380,000 | Feb 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Hillhouse Investment Management, Ltd.owner
- John Hohnekerdirector
- James Paul KastenmayerGeneral Counsel
- Winston KungChief Financial Officer
- Robin LaChapelleChief Operating Officer
- Stuart LutzkerPresident of R&D
- Chris Noletdirector
- Merdad Parseyofficer, director
- Kristine Petersondirector
- Zhengbin YaoPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.